Top-News

Rigel Pharmaceuticals Aktie News

Aktie
WKN:  A40EFY ISIN:  US7665597024 US-Symbol:  RIGL Branche:  Biotechnologie Land:  USA
48,52 $
+1,14 $
+2,41%
41,670 € 18:24:22 Uhr
Depot/Watchlist
Marktkapitalisierung *
645,21 Mio. €
Streubesitz
17,08%
KGV
17,34
Index-Zuordnung
-

Rigel Pharmaceuticals News

26.11.25 - PR Newswire
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference PR Newswire
17.11.25 - PR Newswire
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology PR Newswire
12.11.25 - PR Newswire
Rigel to Present at the Jefferies Global Healthcare Conference in London
Rigel to Present at the Jefferies Global Healthcare Conference in London PR Newswire
04.11.25 - PR Newswire
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
03.11.25 - PR Newswire
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition PR Newswire
29.10.25 - PR Newswire
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update PR Newswire
08.10.25 - PR Newswire
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-​Risk MDS PR Newswire
03.10.25 - PR Newswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
26.08.25 - PR Newswire
Rigel to Participate in Upcoming September Investor Conferences
Rigel to Participate in Upcoming September Investor Conferences PR Newswire
05.08.25 - PR Newswire
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
29.07.25 - PR Newswire
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update PR Newswire
07.07.25 - PR Newswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
28.05.25 - PR Newswire
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel to Present at the Jefferies Global Healthcare Conference PR Newswire
22.05.25 - PR Newswire
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress PR Newswire
06.05.25 - PR Newswire
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire
29.04.25 - PR Newswire
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update PR Newswire
27.03.25 - PR Newswire
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation PR Newswire
10.03.25 - PR Newswire
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors PR Newswire
04.03.25 - PR Newswire
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update PR Newswire
25.02.25 - PR Newswire
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »